Cara Therapeutics Inc (NASDAQ:CARA)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research note issued to investors on Friday. They currently have a $29.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 72.31% from the stock’s current price.

CARA has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Cara Therapeutics in a report on Monday, April 24th. Janney Montgomery Scott set a $20.00 target price on shares of Cara Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 11th. Raymond James Financial, Inc. reaffirmed a “market perform” rating and set a $30.00 target price on shares of Cara Therapeutics in a report on Friday, April 28th. Vetr raised shares of Cara Therapeutics from a “strong sell” rating to a “sell” rating and set a $17.31 target price on the stock in a report on Thursday, March 30th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $23.00 target price on shares of Cara Therapeutics in a report on Friday, March 3rd. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Cara Therapeutics presently has a consensus rating of “Buy” and an average target price of $26.17.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics (NASDAQ:CARA) opened at 16.83 on Friday. The company’s market capitalization is $547.09 million. The company has a 50-day moving average of $16.69 and a 200-day moving average of $13.63. Cara Therapeutics has a 52 week low of $4.35 and a 52 week high of $20.90.

Cara Therapeutics (NASDAQ:CARA) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $0.11 million. The company’s revenue for the quarter was up 12900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) earnings per share. On average, equities research analysts anticipate that Cara Therapeutics will post ($2.35) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Cara Therapeutics Inc (CARA) Receives “Overweight” Rating from Cantor Fitzgerald” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/05/20/cara-therapeutics-inc-cara-receives-overweight-rating-from-cantor-fitzgerald.html.

In related news, major shareholder Ventures Vi Lp Rho purchased 500,000 shares of the firm’s stock in a transaction dated Friday, March 31st. The shares were purchased at an average price of $18.19 per share, with a total value of $9,095,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Several institutional investors have recently modified their holdings of the company. Disciplined Growth Investors Inc. MN acquired a new stake in shares of Cara Therapeutics during the fourth quarter worth about $8,251,000. FMR LLC boosted its stake in shares of Cara Therapeutics by 931.6% in the first quarter. FMR LLC now owns 938,776 shares of the biopharmaceutical company’s stock worth $17,264,000 after buying an additional 847,777 shares during the period. Chescapmanager LLC acquired a new stake in shares of Cara Therapeutics during the fourth quarter worth about $6,365,000. RHO Capital Partners Inc. boosted its stake in shares of Cara Therapeutics by 16.3% in the first quarter. RHO Capital Partners Inc. now owns 3,568,057 shares of the biopharmaceutical company’s stock worth $65,617,000 after buying an additional 500,000 shares during the period. Finally, Jennison Associates LLC acquired a new stake in shares of Cara Therapeutics during the first quarter worth about $5,517,000. 43.29% of the stock is currently owned by hedge funds and other institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

12 Month Chart for NASDAQ:CARA

Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.